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Abstract
A 2016 task force convened by multiple societies proposed a new definition of 
sepsis, termed Sepsis 3. The new clinical diagnosis of sepsis is based on variation 
points in the Sequential (Sepsis-related) Organ Assessment Score (SOFA) and 
excluded Systemic Inflammatory Response Syndrome (SIRS) as a criterion for 
defining the diagnosis. Although the new definitions have provided improvements 
in understanding the disease, the main concern generated by Sepsis 3 is the reduced 
sensitivity to detect cases that might have an unfavorable course, mainly in early 
conditions. By limiting the diagnosis to organic dysfunction, the new concept tends 
to select a more severely ill population. In this way, biomarkers to diagnose sepsis 
may allow early intervention, which can reduce the risk of death. Although lactate is 
currently the most commonly used biomarker to identify sepsis, other biomarkers 
may help to enhance lactate’s effectiveness and may be used as a tool for staging the 
disease, prognosis, and response to intervention. The objective of this chapter is to 
present possible new biomarkers that are clinically relevant.
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1. Introduction
The first definition of sepsis was described in a consensus conference in 1991. 
Known as Sepsis 1, it advocated the hypothesis that infection was directly propor-
tional to the systemic inflammatory response syndrome (SIRS). Ten years later, in a 
new conference (Sepsis 2), the SIRS diagnostic method was already questioned by 
the scientific community about its low specificity. However, in the current situ-
ation, Sepsis 2 did not offer many alternatives because of the lack of evidence to 
substantiate the above arguments [1, 2].
Although SIRS criteria have been described for more than three decades as a host’s 
clinical expression to systemic infection and have contributed greatly to the under-
standing of sepsis in various pathophysiological areas, the need for a new conference 
in 2016 was recognized, where the sepsis’ concepts were reviewed again [2, 3].
Sepsis 3 was proposed by the Society of Critical Care Medicine (SCCM) together 
with the European Society of Intensive Care Medicine (ESICM), which established 
that the disease is linked to life-threatening organic dysfunction that is secondary to 
the body’s unregulated responses to the infection. This new definition extinguished 
the term of severe sepsis and completely abandoned the use of SIRS in the diagnosis 
of sepsis [4].
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In order to promote a new and more sensitive diagnostic method than the 
previous one, the score of sequential organ failure assessment (SOFA) was insti-
tuted. Due to the complexity of the SOFA’s rapid completion and the concern of the 
impossibility of a fast and early disease identification, “quick SOFA” (qSOFA) was 
also established in Sepsis 3 [3].
Despite the improvements obtained through Sepsis 3, in the same year of the new 
guidelines, Williams et al. [4] demonstrated in 2016 that the new diagnostic model 
is not very sensitive in the early stages of disease. These observations are of great 
clinical relevance because the treatment of sepsis is more effective in early stages.
One of the alternatives used for the early diagnosis of patients in several diseases 
is the Point-of-Care Testing (POCT), a laboratory test carried out in the places 
where the intensive treatment is done. POCT has become popular among physicians 
because its agility in the patients’ diagnosis has been shown to be effective, includ-
ing requiring fewer samples collected from the patient [5].
Unlike traditional laboratory tests, POCT does not require a permanent dedi-
cated space, since it has kits and instruments that can be transported to where the 
patient is, thus immediately allowing the dosage of several substances, not only 
in hospital or professional environments, and can be operated by patients in their 
home [6].
Currently, POCT is used to test a range of pathological conditions, including 
diabetes, hypertension, hyperlipidemia, and asthma, as well as monitoring of bone 
density, body composition, and anticoagulation, and these tests are expanding 
rapidly (from 12 to 15% annually) [6].
Despite the great validity of the POCT test, this method presents operational 
and environmental instability and is difficult to standardize in intensive care set-
tings [7, 8]. In addition, the clinical status of patients with sepsis is very unstable 
and the disease severity usually changes abruptly [1]. Thus, it is necessary to 
recognize new specific and sensitive biological markers for the sepsis diagnosis.
Biomarkers were defined by the National Institute of Health as a characteristic 
that should be measured and served as an indicator of a normal, pathological state 
or a response to a pharmacological agent. They shall be characterized by accuracy 
and reproducibility and may be used as important tools for diagnosis, as well as 
promoting early diagnosis, indicating the stage of the disease, prognosis, and 
mechanisms of intervention.
More than 100 biomarkers have already been described and proposed for sepsis; 
combinations between them have also been demonstrated. However, due to the 
different stages of severity observed in sepsis in the most diverse populations, it has 
been complicated to define which marker can be used as a parameter to improve 
therapeutic strategies. Therefore, for sepsis, a good biomarker has to be able to 
identify early alterations in order to prevent multiple organ dysfunction and conse-
quently reduce the mortality of patients with this pathology.
New biomarkers could promote better monitoring of the patient’s condition and, 
possibly, a more accurate definition of the disease prognosis. This chapter aims to 
describe the biological markers already established for sepsis, as well as to cite those 
that in our opinion show promising results.
2. Established biological markers
2.1 Lactate
Lactate (or lactic acid) is the anaerobic glycolysis end product, and its blood 
levels increase significantly in the hypoperfusion or hypoxia cases. Due to an 
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imbalance between lactate production and lactate clearance in patients with sepsis, 
hyperlactatemia is a common condition in these patients [9, 10].
The first study that connected the production of lactate with sepsis was per-
formed by Bakker et al. [11] in 1991. In this study, they demonstrated that the 
tissues of patients with sepsis or septic shock did not adequately use the O2 molecule 
and that survivors of the disease had lower blood lactate levels than those who died 
from the disease.
Five years after this finding, Bernardin et al. [12] demonstrated that the changes 
in the blood lactate level occur within the first 24 hours of treatment, and in addi-
tion to blood pressure fluctuation, may be strong indicators of short-term survival 
prognosis in patients diagnosed with septic shock.
In a paper published in 2013, a Brazilian clinical care research group has 
demonstrated that hyperlactatemia can be caused by mitochondrial dysfunction 
and the use of adrenergic drugs in the condition of septic shock [13]. Léguillier 
et al. [14] demonstrated in 2018 that the lactate dosage, associated with POCT, 
bring a possible new strategy for the early treatment of patients with suspicion of 
sepsis [14].
As predicted in Sepsis 3, the most common use of lactate dosage is in the dif-
ferentiation between sepsis and septic shock in intensive care units (ICUs), and this 
information is very important and useful for medical professionals.
However, Guo et al. [15] demonstrated in their study that an isolated and simple 
dosage of arterial lactate is not satisfactory in recognizing the sepsis prognosis. 
Therefore, they suggest that such dosages need to be supported by results from 
other biological markers, such as C-reactive protein (CRP), B-type natriuretic 
peptide (BNP), and N-terminal proBNP (NT-proBNP).
2.2 C-reactive protein
C-reactive protein (CRP) is an acute inflammatory phase protein produced in 
the liver, currently believed to be a reliable indicator of inflammation and tissue 
damage, as it is elevated in cases of infection, inflammatory response, damage, and 
necrosis of the tissue [16]. Among its actions are platelet activation, chemotaxis 
acceleration, and enhancement of cell-mediated immunity by promoting phagocy-
tosis [17].
One of the first studies to correlate CRP with sepsis was conducted in 1987 
by Mustard et al. In this study, it was observed that postoperative CRP levels can 
predict septic complications even before its clinical manifestation [18].
This protein is also used to differentiate the sepsis of a noninfectious systemic 
inflammatory response syndrome in trauma patients, in which the high level of this 
protein in the first 4 days after injury is a reliable indication of infection [19].
In 2013, a study conducted at the Department of Pediatrics at Yonsei University 
of Medicine showed that high levels of CRP in the mother may indicate a risk of 
infection of the newborn and that these values would be related to the severity of 
the disease presented by these babies [16].
Also, in 2013, Oliveira et al. [20] compared CRP with another established 
biomarker, procalcitonin (PCT). In this study, it was observed that the protein is 
as effective as PCT to guide antibiotic therapy in patients with sepsis, showing that 
the group guided by CRP levels required less treatment time when compared to the 
control groups.
In a study published in 2017, Wang et al. [21] once again correlated CRP with 
sepsis when comparing the CRP’s serum level with those of other proinflammatory 
cytokines, suggesting that this would be a potential target for the treatment of 
patients with sepsis.
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However, although there is considerable sensitivity in the CRP oscillation to 
describe the disease intensity in already diagnosed patients, this biomarker has low 
specificity in determining sepsis, which prevents CRP from being alone an indicator 
for the diagnosis of the pathology [15].
2.3 B-type natriuretic peptide
B-type natriuretic peptide (BNP) is a cardiac hormone with natriuretic, diuretic, 
and vasodilatory properties. It is produced by the ventricular myocardium in 
response to the stretching of the cardiac muscle, having as its main role the cardiac 
pressure regulation and homeostasis of the intravascular volume [22]. In this 
sense, septic shock is recognized as a condition that causes severe changes in blood 
pressure.
BNP or its inactive N-terminal proBNP cleavage product (NT-proBNP) is mainly 
used as a biomarker for congestive heart failure [23]. However, Papanikolaou et al. 
[24] demonstrated in 2014 that the severity of sepsis is the major determinant of 
BNP increase in the disease-induced myocardial depression in patients with a septic 
shock. In addition, the same study suggests that the increase in BNP serum levels on 
the second day of the condition is a strong indication of a poor prognosis.
However, due to the inconsistency of results and the specificity limitations, 
harsh criticism of this biomarker use has recently arisen, demonstrating the 
need for further studies to validate the use of this as a biomarker in the sepsis 
condition [25].
It is currently believed that BNP and NT-proBNP have moderate potential to 
assess the diseased patients’ prognosis. As Bai demonstrated in his meta-analysis 
published in 2018, the peptide can be used as a tool for defining how the condition 
will evolve, but further studies are needed to assess the real importance of BNP in 
the clinic [26].
2.4 Procalcitonin
Procalcitonin (PCT) is a prohormone precursor of calcitonin produced by 
thyroid C cells. Under normal conditions, PCT is not detected in the circulation; 
however, in situations of great stress, such as sepsis, it is possible to observe a high 
extrathyroidal production of PCT. PCT is currently used as a tool to differentiate 
bactericidal infection from other inflammatory and infectious processes [27].
PCT is correlated with sepsis since 1993 when Assicot et al. [28] demonstrated 
that this protein was detectable in the plasma of diseased patients and with other 
types of infection. Since then, studies have demonstrated the efficacy of this tool 
in the prognosis of patients with sepsis, as demonstrated in the review published in 
2001 by Meisner [29], in which it was observed that the PCT’s concentration during 
the sepsis and SIRS stages is high and is directly proportional to the severity of the 
condition.
This method provides additional information to the diagnosis by other param-
eters of an inflammatory response; such additional information is not provided 
by conventional parameters of systemic inflammation. Mustafić et al. [30] also 
demonstrated in 2018 that it is possible to use PCT to reveal the disease severity and 
prevent a fatal outcome for the patient with sepsis.
In the same year, Bilgili et al. [31] demonstrated that PCT can differentiate even 
gram-negative bacteremia from a Gram-positive one, noting that protein values 
are higher in patients infected with Gram-negative bacteria. However, in these 
cases, PCT should be used only as a support tool for predictive purposes  
in diagnostic tests.
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Several studies have shown that PCT’s serum levels may be a guide in antibi-
otic therapy and can also be used to safely reduce the excessive exposure of these 
patients to drugs, thus reducing the adverse effects of sepsis treatment and avoiding 
the development of multiresistant bacteria [20].
Considering several studies cited in this chapter, the sepsis survival campaign 
published in 2017 suggested that the PCT monitoring should be used to verify the 
dosage and duration of antimicrobial treatment in patients with sepsis [32].
In Table 1, we summarize some parameters that reveal the predictive potential 
of the biomarkers mentioned above. Among them, we emphasize the sensitivity 
and specificity of each biomarker demonstrated by the ROC curve. The area under 
the ROC curve (AUC) represents the performance of the biomarker. We also speci-
fied in the table the positive and negative predictive values for each marker.
3. Promising biomarkers
3.1 Receptor for advanced glycation end products
The receptor for advanced glycation end products (RAGE) recipient is a stan-
dard recognition receptor that participates in a wide variety of physiological and 
pathological processes, such as diabetic complications, cancer, atherosclerosis, and 
inflammation.
The studies that relate soluble RAGE (sRAGE), the extracellular domain of 
RAGE, to the sepsis are very recent since even the discovery of this receptor’s 
soluble form occurred in 2009 [37]. It has been reported that an increase in the level 
of sRAGE would be a protective mechanism since its presence in plasma contrib-
utes to the removal or neutralization of ligands for RAGE, thus acting as a “false” 
receptor [38]. However, Wang et al. [39] reported a deletion effect of sRAGE in the 
inflammatory process, since it would bind to CD11b receptors of leukocytes, thus 
propagating inflammation.
Based on these contradictory results in scientific literature, in 2014, our group 
published a study demonstrating a positive correlation between serum levels of 
sRAGE with IFN-γ in patients with sepsis. We also observed significant correlations 
between levels of IL-1α, IL-6, IL-8, IL-10, and IP-10 and sRAGE in patients with 
septic shock. We concluded that sRAGE blood levels may be associated with the 
mortality of patients with septic shock [35].
Further studies support this assertion, such as the study by Matsumoto et al. 
[40] demonstrated that the sRAGE serum level of patients with sepsis increases 
directly proportional to the severity of the disease, suggesting that sRAGE reflects 
on the RAGE’s signaling pathway inducing an excessive inflammatory response 
involved in endothelial injury and coagulopathy.
Biomarker Sensitivity (%) Specificity (%) AUC NPV PPV References
Lactate 58.3 88.1 0.66 78.7 73.7 [33]
CRP 66 80 0.81 88 51 [34]
Pro-BNP 70.8 47.6 0.66 74.1 43.6 [33]
PCT 88 80 0.87 95 57 [33, 34]
sRAGE 75 85 — — — [35, 36]
Table 1. 
Biomarkers and their predictive parameters in sepsis.
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In the same year, Wang et al. [41] demonstrated that the decrease in sRAGE 
levels in mice results in improved sepsis-induced lung damage, thus decreasing 
mortality in this condition. Another study by Narvaez-Rivera et al. [36] demon-
strated in 2015 that sRAGE’s level in the plasma is high in patients with community-
acquired pneumonia associated with sepsis and is also an independent factor for the 
likelihood of a fatal outcome.
Further studies are still needed to elucidate the mechanism of action of sRAGE 
in sepsis and septic shock; however, this receptor appears to be a promising biologi-
cal marker for sepsis.
3.2 Nitric oxide
Nitric oxide (NO) is a highly reactive soluble gas that is endogenously synthesized 
by the three isoforms of the nitric oxide synthase enzyme (NOS), neuronal NOS 
(nNOS or NOS1), inducible NOS (iNOS or NOS2), and endothelial NOS (eNOS or 
NOS3). These molecules are known to be highly involved in cardiovascular homeosta-
sis, so recent research has focused on its action on sepsis-induced heart disease [42].
In 2014, Nardi et al. [43] showed an increased NOS1 expression in vascular tis-
sues in the sepsis condition, suggesting that this molecule could be a way to justify 
vascular dysfunction induced by the disease. This study suggests that the inhibition 
of this isoform may be an alternative to restore the effectiveness of vasopressors in 
later cases of sepsis.
In the same year, Martin et al. reported an association between NOS2 and NOS3 
with sepsis. In the study, the authors suggest that this association could be related to 
the high level of NO in the blood plasma, which could consequently induce a failure 
of hemodynamics and increase the mortality of septic patients [44].
More recently, the critical care department of the First People’s Hospital in 
Chun’an (China) demonstrated that monitoring changes in NO serum and amyloid 
A levels can be an efficient tool for defining patient prognosis and, when compared 
with CRP, would present better clinical results [45]. Despite the positive results on 
the use of nitric oxide as a biological marker for sepsis, many studies are still needed 
to fully understand its role in this condition.
3.3 Haptoglobin
Haptoglobin (Hp) is a protein whose main biological function is to bind free hemo-
globin (Hb) and to prevent the loss of iron and subsequent kidney damage following 
intravascular hemolysis. When red cells are lysed, Hb binds to circulating Hp forming 
the Hp-Hb complex, which is then degraded by the reticuloendothelial system [46].
Although it is recognized that Hp is predominantly synthesized in the liver, 
studies reveal the expression of this protein also in other parts of the body, such as 
the lung, kidneys, heart, spleen, thymus, and brain [47–49]. There are reports that 
Hp levels are influenced by the acute inflammatory process and that such protein 
exerts an important antimicrobial and antioxidant function [50–52].
It is known that some patients with sepsis present deformity of hemoglobins, 
thus causing lysis of these cells and releasing them into the circulation [53]. In this 
context, the decrease in blood levels of Hp has already been described as a factor 
linked to increased mortality in patients diagnosed with sepsis, and, in animal mod-
els of sepsis, Hp supplementation has been shown to be able to decrease biomarkers 
of acute systemic inflammation [54, 55].
Even with this result, prospective and randomized studies are still needed to 
better elucidate the potential protective effects of endogenous and exogenous 
haptoglobin against the deleterious effects of free hemoglobin in septic patients.
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3.4 Cytokines as biomarkers
Sepsis is characterized by two phases: a period of hyperinflammation, where the 
innate immune system is overactivated leading to production of proinflammatory 
cytokines such as TNF, IL-1b, IL-6, and IL8, and another period of immunosup-
pression where both adaptive and innate immunity are acting [56]. Clinical trials 
in septic patients showed an increase in the above-mentioned pro-inflammatory 
cytokines [57, 58].
However, contradictory results have been obtained for TNF and IL-1b. For 
example, the treatment of septic patients with anti-TNF antibodies did not affect 
the clinical outcome of patients [59]. In addition, these cytokines are not altered 
only in sepsis, after surgery or in autoimmune disease they are also altered and 
therefore are not specific.
On the other hand, studies have reported that IL-6 shows great promise as a 
biomarker [60–63]. Like TNF and IL-1b, IL-6 is not altered only in sepsis; neverthe-
less, several studies have shown its importance in the prognosis of sepsis presenting 
strong correlations with patient mortality [62, 63]. These results were also shown 
in an animal model of acute septic peritonitis (CLP) [61]. In this way, IL6 levels can 
show which patients may develop severe sepsis, and this reflects on possible inter-
ventions. Like IL6, IL8 has also been mentioned as a prognostic biomarker in septic 
patients especially in the early stages of the disease [64].
In the immunosuppression stage, IL-10 plays a key role in development of CARS 
trying to reduce hyperinflammation [65]. Therefore, studies have shown that high 
levels of IL-10 are correlated with a worse outcome and death [65–67]. In neonatal 
sepsis, IL-10 also proved to be an accurate biomarker. Figure 1 illustrates the model 
proposed by van der Poll and van Deventer [68], emphasizing that the development 
of CARS still occurs in the pro-inflammatory phase of the disease. Thus, the mortal-
ity observed in the early stages of sepsis may be related to the hyper-inflammatory 
phase, and the late-stage deaths are related to the immunosuppressive phase as well 
as to secondary infections [56].
Figure 1. 
Stages of sepsis and cytokine profile.
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Accordingly, the cytokine profile in the septic patient could provide information 
about the stage of the disease and the patient’s prognosis, contributing to a better 
intervention. In addition, we currently have a multiplex assay that simultaneously 
measures multiple cytokines with small plasma samples; however, this information 
should be interpreted with caution since the dosages of some cytokines in septic 
patients appear unclear in the literature needing to be standardized. Once standard-
ized, the multiplex assay may be useful in the clinic.
3.5 Biomarker combinations
As previously seen, no biomarker has 100% sensitivity or specificity capable of 
predicting the clinical outcome for the patient with sepsis. Studies have shown that 
combining biomarkers may facilitate diagnosis and predict the outcome more faithfully.
As above mentioned, Guo demonstrated that the combination among lactate, 
CRP and BNP, or NT-proBNP has greater specificity for prognosis than isolated 
lactate dosage, being 100 and 69.23%, respectively [15]. Yu and colleagues [45] also 
showed that combining NO with SAA is an important tool to improve the prognosis 
of septic patients.
Clinical scores are not effective in early identification of infection in critically 
ill patients; however, combining these scores with biomarkers allows an early and 
accurate identification of sepsis. For example, Yoo and co-workers found that 
combining Modified Early Warning Score (MEWS), a tool for monitoring sepsis, 
with blood lactate levels was efficient for early identification of the disease [69]. 
The same was found by Bozza et al. [70] and Oberholzer et al. [71] when they com-
bined the levels of MPC-1 or IL-6 with APACHE II, respectively, and found greater 
accuracy in the prognosis of the patients.
Other biomarkers aforementioned are also more accurate when combined. Han 
et al. showed that the association with CRP and PCT is an important tool to differenti-
ate bacterial sepsis from other possible types of infection in critically ill patients [72]. 
Angeletti et al. [73] also showed that the combination among PCT, Tumor Necrosis 
Factor-α (TNF-α), and the adrenomedullin hormone fragment may help in the prior 
diagnosis and prognosis of septic patients, thus optimizing treatment of patients.
As mentioned above, IL-6, IL10, and IL-8 cytokines may also be altered in septic 
patients. In this way, combining cytokine dosage with another biomarker may 
improve the diagnosis. For example, it has been shown that combining CRP dosage 
with IL8 and IL2 was useful in the diagnosis of neonatal sepsis [74]. Another study 
with adult septic patients measured TNF, IL6, and IL10 and demonstrated that 
combining IL6 (pro-inflammatory) with IL10 (anti-inflammatory) cytokines was 
useful in establishing the prognosis. Moreover, high levels of IL-6 and IL-10 were 
related to high patient mortality [75].
Another combination has been demonstrated by Wong and colleagues who 
showed that interleukin-27 (IL-27) when combined with PCT can improve the diag-
nostic accuracy in septic patients when compared to each biomarker alone [76]. In 
2012, Andaluz-Ojeda et al. [66] using the multiplex assay demonstrated that combin-
ing pro—IL-6 and IL-8—and anti-inflammatory cytokine—IL10 and MCP-1—levels 
was more predictive than analyzing each cytokine separately. Furthermore, high 
levels of these cytokines were positively correlated with the patient’s mortality rate.
4. Conclusion
In this chapter we have outlined some biological markers established in the 
literature and that have recognized clinical relevance for sepsis, such as CRP [18], 
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lactate [11], BNP [24], and procalcitonin [28]. In addition, we also present some 
biomarkers that we believe are promising for the disease (sRAGE, NO, and 
haptoglobin).
The choice of the promising biomarkers cited in this chapter considered the 
clinical relevance of each of them (demonstrated by several studies) and our expe-
rience in the field. However, we recognize that there is a broad spectrum of quality 
papers published in the area of biomarkers for sepsis and that unfortunately those 
were not mentioned in this chapter.
Among the new research targets, we believe that sRAGE may be one of the most 
promising ones in severe sepsis. Our group demonstrated that this soluble receptor 
can be used as a tool to define the death prognosis of patients with septic shock, 
presenting a sensitivity of 75% and specificity of 85% [35].
In conclusion, it is noticeable that the currently used methods, even effective 
ones, require optimization. In this sense, one of the alternatives is combining 
biological markers, such as those exposed in this chapter, in order to increase the 
sensitivity and specificity of the diagnosis and prognosis of patients with sepsis, so 
that the treatment of this disease is increasingly early and efficient.
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